{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:23:29Z","timestamp":1790015009978,"version":"4.0.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.ejps.2014.06.023","type":"journal-article","created":{"date-parts":[[2014,7,8]],"date-time":"2014-07-08T00:01:50Z","timestamp":1404777710000},"page":"45-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["A physiologically based pharmacokinetic model for Valproic acid in adults and children"],"prefix":"10.1016","volume":"63","author":[{"given":"Kayode","family":"Ogungbenro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Aarons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejps.2014.06.023_b0005","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/dmd.108.022426","article-title":"Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10","volume":"37","author":"Argikar","year":"2009","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.ejps.2014.06.023_b0010","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/clpt.2012.64","article-title":"Physiologically based pharmacokinetic (PBPK) modeling in children","volume":"92","author":"Barrett","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.ejps.2014.06.023_b0015","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/bdd.2510060105","article-title":"Pharmacokinetics of valproic acid in volunteers after a single dose study","volume":"6","author":"Bialer","year":"1985","journal-title":"Biopharm. Drug Dispos."},{"issue":"2","key":"10.1016\/j.ejps.2014.06.023_b0020","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2710.2003.00538.x","article-title":"Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage","volume":"29","author":"Bondareva","year":"2004","journal-title":"J. Clin. Pharm. Ther."},{"issue":"1","key":"10.1016\/j.ejps.2014.06.023_b0025","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-2125.1983.tb02151.x","article-title":"Pharmacokinetics of valproic acid in young and elderly subjects","volume":"16","author":"Bryson","year":"1983","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejps.2014.06.023_b0030","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S0022-3476(85)80097-4","article-title":"Comparison of steady-state pharmacokinetics of valproic acid in children between monotherapy and multiple antiepileptic drug treatment","volume":"106","author":"Chiba","year":"1985","journal-title":"J. Pediatr."},{"issue":"9242","key":"10.1016\/j.ejps.2014.06.023_b0035","first-page":"1638","article-title":"Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial","volume":"356","author":"Chiron","year":"2000","journal-title":"STICLO study group. Lancet"},{"issue":"1\u20132","key":"10.1016\/j.ejps.2014.06.023_b0040","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0920-1211(02)00251-6","article-title":"Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy","volume":"53","author":"Cloyd","year":"2003","journal-title":"Epilepsy Res."},{"issue":"1","key":"10.1016\/j.ejps.2014.06.023_b0045","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/clpt.1993.5","article-title":"Valproic acid pharmacokinetics in children. IV. Effects of age and antiepileptic drugs on protein binding and intrinsic clearance","volume":"53","author":"Cloyd","year":"1993","journal-title":"Clin. Pharm. Ther."},{"issue":"6_2","key":"10.1016\/j.ejps.2014.06.023_b0050","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/archinte.1916.00080130010002","article-title":"A formula to estimate the approximate surface area if height and weight be known","volume":"17","author":"DuBois","year":"1916","journal-title":"Arch. Int. Med."},{"issue":"3","key":"10.1016\/j.ejps.2014.06.023_b0055","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eplepsyres.2006.11.005","article-title":"Distinct absorption characteristics of oral formulations of valproic acid\/divalproex available in the United States","volume":"73","author":"Dutta","year":"2007","journal-title":"Epilepsy Res."},{"issue":"3","key":"10.1016\/j.ejps.2014.06.023_b0060","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1460-9592.2010.03473.x","article-title":"Knowledge-driven approaches for the guidance of first-in-children dosing","volume":"21","author":"Edginton","year":"2011","journal-title":"Pediatr. Anesthesia"},{"issue":"7","key":"10.1016\/j.ejps.2014.06.023_b0065","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2165\/00003088-200645070-00004","article-title":"A mechanistic approach for the scaling of clearance in children","volume":"45","author":"Edginton","year":"2006","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.ejps.2014.06.023_b0070","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/j.1552-4604.1985.tb02836.x","article-title":"A multivariable analysis of factors governing the steady-state pharmacokinetics of valproic acid in 52 young epileptics","volume":"25","author":"Hall","year":"1985","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejps.2014.06.023_b0075","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0022-3476(78)80601-5","article-title":"Geometric method for measuring body surface area: a height\u2013weight formula validated in infants, children, and adults","volume":"93","author":"Haycock","year":"1978","journal-title":"J. Pediatr."},{"issue":"6","key":"10.1016\/j.ejps.2014.06.023_b0080","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.tpj.6500210","article-title":"Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes","volume":"3","author":"Ho","year":"2003","journal-title":"Pharmacogenomics J."},{"issue":"4","key":"10.1016\/j.ejps.2014.06.023_b0085","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1528-1157.1990.tb05494.x","article-title":"Epidemiology of severe myoclonic epilepsy of infancy","volume":"31","author":"Hurst","year":"1990","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.ejps.2014.06.023_b0090","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0378-5173(85)90184-X","article-title":"Physiologically based pharmacokinetics of valproic acid in rabbits","volume":"27","author":"Ichimura","year":"1985","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.ejps.2014.06.023_b0095","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1208\/s12248-009-9099-y","article-title":"Population-based mechanistic prediction of oral drug absorption","volume":"11","author":"Jamei","year":"2009","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2014.06.023_b0100","first-page":"e80","article-title":"Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in children","volume":"2","author":"Jiang","year":"2013","journal-title":"CPT: Pharmacomet. Syst. Pharmacol."},{"issue":"9","key":"10.1016\/j.ejps.2014.06.023_b0105","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2165\/00003088-200645090-00005","article-title":"Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children","volume":"45","author":"Johnson","year":"2006","journal-title":"Clin. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.ejps.2014.06.023_b0110","first-page":"1085","article-title":"Pharmacokinetic studies with Valproic acid in man","volume":"27","author":"Klotz","year":"1977","journal-title":"Arzneimittel-Forsch"},{"issue":"6","key":"10.1016\/j.ejps.2014.06.023_b0115","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/cpt1977216736","article-title":"Pharmacokinetics and bioavailability of sodium valproate","volume":"21","author":"Klotz","year":"1977","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.ejps.2014.06.023_b0120","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/clpt.2012.19","article-title":"Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials","volume":"91","author":"Leong","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.ejps.2014.06.023_b0125","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/clpt.1990.144","article-title":"Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid","volume":"48","author":"Levy","year":"1990","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.ejps.2014.06.023_b0130","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0022-3565(25)31137-7","article-title":"Serum-protein binding and pharmacokinetics of Valproate in man, dog, rat and mouse","volume":"204","author":"Loscher","year":"1978","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.ejps.2014.06.023_b0135","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF00313758","article-title":"Plasma concentrations of Valproate during maintenance therapy in epileptic children","volume":"228","author":"Lundberg","year":"1982","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.ejps.2014.06.023_b0140","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1208\/s12248-013-9451-0","article-title":"A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam","volume":"15","author":"Maharaj","year":"2013","journal-title":"AAPS J."},{"issue":"5","key":"10.1016\/j.ejps.2014.06.023_b0145","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1365-2125.2000.00191.x","article-title":"Apparent autoinduction of valproate beta-oxidation in humans","volume":"49","author":"McLaughlin","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejps.2014.06.023_b0150","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jpeds.2010.10.035","article-title":"Dravet syndrome: inroads into understanding epileptic encephalopathies","volume":"158","author":"Morse","year":"2011","journal-title":"J. Pediatr."},{"issue":"2","key":"10.1016\/j.ejps.2014.06.023_b0155","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1528-1157.1982.tb05063.x","article-title":"The pharmacokinetics of valproic acid after oral and parenteral administration in healthy-volunteers","volume":"23","author":"Nitsche","year":"1982","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.ejps.2014.06.023_b0160","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1365-2125.1978.tb01713.x","article-title":"Pharmacokinetics of Valproic acid after oral and intravenous administration","volume":"5","author":"Perucca","year":"1978","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejps.2014.06.023_b0165","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1365-2125.1978.tb01663.x","article-title":"Disposition of sodium Valproate in epileptic patients","volume":"5","author":"Perucca","year":"1978","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejps.2014.06.023_b0170","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/jps.20322","article-title":"Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases","volume":"94","author":"Rodgers","year":"2005","journal-title":"J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.ejps.2014.06.023_b0175","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jps.20502","article-title":"Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions","volume":"95","author":"Rodgers","year":"2006","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.ejps.2014.06.023_b0180","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ejps.2009.12.002","volume":"39","author":"Rowland","year":"2010","journal-title":"Eur. J. Pharm. Sci.: Off. J. Eur. Fed. Pharma. Sci."},{"issue":"2","key":"10.1016\/j.ejps.2014.06.023_b0185","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0022-3565(24)37076-4","article-title":"Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid","volume":"283","author":"Sadeque","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"8","key":"10.1016\/j.ejps.2014.06.023_b0190","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/jcph.100","article-title":"Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug\u2013drug interactions","volume":"53","author":"Salem","year":"2013","journal-title":"J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejps.2014.06.023_b0195","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/00007691-199003000-00001","article-title":"Invivo determination of Valproate binding constants during sole and multidrug therapy","volume":"12","author":"Scheyer","year":"1990","journal-title":"Ther. Drug Monit."},{"issue":"1","key":"10.1016\/j.ejps.2014.06.023_b0200","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1124\/jpet.301.1.382","article-title":"In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance","volume":"301","author":"Soars","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7","key":"10.1016\/j.ejps.2014.06.023_b0205","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/j.2042-7158.2011.01282.x","article-title":"No effect of co-administered antiepileptic drugs on in-vivo protein binding parameters of valproic acid in patients with epilepsy","volume":"63","author":"Suzuki","year":"2011","journal-title":"J. Pharm. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejps.2014.06.023_b0210","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2710.2009.01022.x","article-title":"Poor applicability of estimation method for adults to calculate unbound serum concentrations of valproic acid in epileptic neonates and infants","volume":"34","author":"Ueshima","year":"2009","journal-title":"J. Clin. Pharm. Ther."},{"issue":"1","key":"10.1016\/j.ejps.2014.06.023_b0215","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1248\/bpb.34.108","article-title":"Empirical approach for improved estimation of unbound serum concentrations of Valproic acid in epileptic infants by considering their physical development","volume":"34","author":"Ueshima","year":"2011","journal-title":"Biol. Pharm. Bull."},{"issue":"3\u20134","key":"10.1016\/j.ejps.2014.06.023_b0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0146-6453(03)00002-2","article-title":"Basic anatomical and physiological data for use in radiological protection: reference values: ICRP publication 89","volume":"32","author":"Valentin","year":"2002","journal-title":"Ann. ICRP"},{"issue":"3","key":"10.1016\/j.ejps.2014.06.023_b0225","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.braindev.2010.04.003","article-title":"Pharmacokinetics and clinical application of intravenous valproate in Thai epileptic children","volume":"33","author":"Visudtibhan","year":"2011","journal-title":"Brain Dev."},{"issue":"5420","key":"10.1016\/j.ejps.2014.06.023_b0230","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1126\/science.284.5420.1677","article-title":"The fourth dimension of life: fractal geometry and allometric scaling of organisms","volume":"284","author":"West","year":"1999","journal-title":"Science"},{"issue":"5309","key":"10.1016\/j.ejps.2014.06.023_b0235","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1126\/science.276.5309.122","article-title":"A general model for the origin of allometric scaling laws in biology","volume":"276","author":"West","year":"1997","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.ejps.2014.06.023_b0240","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1177\/0091270011428138","article-title":"Population pharmacokinetics of Valproic acid in pediatric patients with epilepsy: considerations for dosing spinal muscular atrophy patients","volume":"52","author":"Williams","year":"2012","journal-title":"J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejps.2014.06.023_b0245","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00003088-198815060-00002","article-title":"Clinical pharmacokinetics of valproic acid\u20131988","volume":"15","author":"Zaccara","year":"1988","journal-title":"Clin. Pharmacokinet."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098714002838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098714002838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T18:06:56Z","timestamp":1746295616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098714002838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":49,"alternative-id":["S0928098714002838"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2014.06.023","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A physiologically based pharmacokinetic model for Valproic acid in adults and children","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2014.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}